Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Shiga Toxin-Mediated Hemolytic Uremic Syndrome: Time to Change the Diagnostic Paradigm?

  • Martina Bielaszewska ,

    To whom correspondence should be addressed. E-mail:

    Affiliation Institute of Hygiene and the National Consulting Laboratory on Hemolytic Uremic Syndrome, University of Münster, Münster, Germany

  • Robin Köck,

    Affiliation Institute of Hygiene and the National Consulting Laboratory on Hemolytic Uremic Syndrome, University of Münster, Münster, Germany

  • Alexander W. Friedrich,

    Affiliation Institute of Hygiene and the National Consulting Laboratory on Hemolytic Uremic Syndrome, University of Münster, Münster, Germany

  • Christof von Eiff,

    Affiliation Institute of Medical Microbiology, University of Münster, Münster, Germany

  • Lothar B. Zimmerhackl,

    Affiliation Department of Pediatrics, University Hospital of Innsbruck, Innsbruck, Austria

  • Helge Karch,

    Affiliation Institute of Hygiene and the National Consulting Laboratory on Hemolytic Uremic Syndrome, University of Münster, Münster, Germany

  • Alexander Mellmann

    Affiliation Institute of Hygiene and the National Consulting Laboratory on Hemolytic Uremic Syndrome, University of Münster, Münster, Germany

Shiga Toxin-Mediated Hemolytic Uremic Syndrome: Time to Change the Diagnostic Paradigm?

  • Martina Bielaszewska, 
  • Robin Köck, 
  • Alexander W. Friedrich, 
  • Christof von Eiff, 
  • Lothar B. Zimmerhackl, 
  • Helge Karch, 
  • Alexander Mellmann



Hemolytic uremic syndrome (HUS) is caused by enterohemorrhagic Escherichia coli (EHEC) which possess genes encoding Shiga toxin (stx), the major virulence factor, and adhesin intimin (eae). However, the frequency of stx-negative/eae-positive E. coli in stools of HUS patients and the clinical significance of such strains are unknown.

Methodology/Principal Findings

Between 1996 and 2006, we sought stx-negative/eae-positive E. coli in stools of HUS patients using colony blot hybridization with the eae probe and compared the isolates to EHEC causing HUS. stx-negative/eae-positive E. coli were isolated as the only pathogens from stools of 43 (5.5%) of 787 HUS patients; additional 440 (55.9%) patients excreted EHEC. The majority (90.7%) of the stx-negative/eae-positive isolates belonged to serotypes O26:H11/NM (nonmotile), O103:H2/NM, O145:H28/NM, and O157:H7/NM, which were also the most frequent serotypes identified among EHEC. The stx-negative isolates shared non-stx virulence and fitness genes with EHEC of the corresponding serotypes and clustered with them into the same clonal complexes in multilocus sequence typing, demonstrating their close relatedness to EHEC.


At the time of microbiological analysis, ∼5% of HUS patients shed no longer the causative EHEC, but do excrete stx-negative derivatives of EHEC that lost stx during infection. In such patients, the EHEC etiology of HUS is missed using current methods detecting solely stx or Shiga toxin; this can hamper epidemiological investigations and lead to inappropriate clinical management. While maintaining the paradigm that HUS is triggered by Shiga toxin, our data demonstrate the necessity of considering genetic changes of the pathogen during infection to adapt appropriately diagnostic strategies.


Hemolytic uremic syndrome (HUS) consists of microangiopathic hemolytic anemia, thrombocytopenia, and renal insufficiency [1]. It usually develops after prodromal diarrhea, which is often bloody [1], [2]. HUS is a leading cause of acute renal failure in children [3] and the mortality during the acute phase reported in recent studies was ∼2% [4][6]; many survivors suffer from renal or non-renal sequelae [1], [3].

The major etiological agents of HUS are enterohemorrhagic Escherichia coli (EHEC) strains belonging to serotype O157:H7 and several other serotypes, including O26:H11/NM (nonmotile), O103:H2/NM, O111:H8/NM, O145:H28/NM, and O157:NM [1], [2], [4][11]. The cardinal virulence traits of EHEC are Shiga toxins (Stx) [12], which cause microvascular endothelial injury in kidneys and other organs resulting in the characteristic thrombotic microangiopathy that forms the histopathological basis of HUS [1], [13]. Stx production is mediated by lysogenic conversion of EHEC with stx-harboring prophages, which integrate into specific sites in their chromosomes [14][16]. These phages can be excised by treatment with UV light, antibiotics, or by various stimuli in the host [14], [16][18]. The majority of EHEC strains associated with HUS also harbor the eae gene encoding intimin [8], [19], which mediates intimate attachment of the bacteria to the intestinal mucosa [20].

Although HUS is typically caused by EHEC, stx-negative/eae-positive (stx−/eae+) E. coli strains are occasionally excreted by patients with HUS [21], [22]. However, the frequency of such strains is unknown, and their origins and clinical significance are poorly understood. To answer these questions, we studied stools from HUS patients, processed so as to detect these variants. We characterized the identified isolates and compared them to EHEC associated with HUS with respect to serotypes, virulence and fitness genes, phenotypes, and multilocus sequence types.


Frequency and serotypes of stx−/eae+ E. coli in stools from patients with HUS

Between 1996 and 2006, stx−/eae+ E. coli strains were isolated from stools of 43 (5.5%) of 787 individual, epidemiologically unrelated HUS patients; additional 440 (55.9%) patients excreted EHEC (Table 1), resulting in an overall isolation rate of 61.4% (483 of 787). In none of the 483 culture-positive patients stx-negative and EHEC strains were found together in the same stool. Thirty-nine (90.7%) of the stx−/eae+ isolates belonged to serotypes O26:H11/NM, O103:H2/NM, O145:H28/NM, and O157:H7/NM (Table 1), which also accounted for the majority (91.1%) of the EHEC isolates (Table 1). One additional stx−/eae+ strain belonged to serotype O121:H19 (which was also found among EHEC; Table 1), and the remaining three were nontypeable (Table 1). Each of the 43 stx−/eae+ strains lacked all known stx alleles. The stools from which these strains were isolated contained neither stx genes as demonstrated by PCR screening of enriched primary stool cultures, nor free Stx as demonstrated by the Vero cell assay on stool filtrates, nor any classic bacterial enteric pathogens including Salmonella, Shigella, and Yersinia spp., and Campylobacter jejuni.

Table 1. Numbers of HUS patients from whom stx-negative/eae-positive E. coli or EHEC strains were isolated and serotypes of the isolates.

Molecular characteristics of stx−/eae+ E. coli isolates

We compared the stx−/eae+ E. coli O26:H11/NM, O103:H2/NM, O121:H19, O145:H28/NM and O157:H7/NM isolated from HUS patients to randomly selected HUS-associated EHEC isolates of corresponding serotypes for the presence of several genes that are known to be typically distributed in EHEC [9], [11], [23][29] (Table 2). The stx−/eae+ strains of each serotype closely resembled EHEC of the corresponding serotype with respect to the presence or absence of putative non-stx virulence genes encoding toxins (EHEC-hlyA, cdt-V), adhesins (iha, lpfAO26, lpfAO157/OI 141, lpfAO157/OI 154, sfpA), and virulence determinants of the O island 122 of E. coli O157:H7 (efa1, sen, pagC), as well as the ter gene cluster and the irp2 and fyuA components of an iron uptake system (Table 2). Moreover, the stx-negative and stx-positive strains within each serotype shared the eae type and fliC gene encoding the flagellin subunit of the H antigen (Table 2). Consistently with the absence of stx, the chromosomal loci which serve as integration sites for stx-converting bacteriophages in EHEC O157:H7/NM (yehV, wrbA, yecE) [14], [15] and EHEC O26:H11/NM (wrbA, yecE) [16] were unoccupied in each of the stx−/eae+ strains of the respective serotypes. This suggests that the absence of stx in these strains was associated with the excision of stx-harboring phages from their chromosomes.

Table 2. Comparison of putative virulence and fitness genes of stx-negative and stx-positive E. coli strains of serotypes O26:H11/NM, O103:H2/NM, O121:H19, O145:H28/NM, and O157:H7/NM.

Comparison of phenotypes of stx−/eae+ E. coli and EHEC

The stx−/eae+ E. coli isolates shared with EHEC of the corresponding serotypes several diagnostically useful phenotypes (Table 3), but, in contrast to EHEC, their culture supernatants were not toxic to Vero cells (Table 3), the cell line that is sensitive to all Stx variants described until now. This suggests that these strains did not produce Stx encoded by stx gene(s) that might have been undetectable with our PCR protocol.

Table 3. Comparison of phenotypes of stx-negative and stx-positive E. coli strains of serotypes O26:H11/NM, O103:H2/NM, O121:H19, O145:H28/NM, and O157:H7/NM.

Multilocus sequence typing (MLST) analysis of stx−/eae+ E. coli and EHEC

The phylogenetic relationships between the stx−/eae+ E. coli O26:H11/NM, O103:H2/NM, O121:H19, O145:H28/NM, and O157:H7/NM and EHEC of the same serotypes were determined by MLST analysis of randomly selected strains (Figure 1). The stx-negative and stx-positive strains of each serotype shared the same sequence type or at least six of the seven alleles investigated [30] and clustered therefore into the same clonal complex (Figure 1). In contrast, the stx-negative strains of the five different serogroups showed no close relationship based on their allelic profiles.

Figure 1. Phylogenetic relatedness of stx-negative and stx-positive E. coli strains within serotypes O26:H11/NM, O103:H2/NM, O121:H19, O145:H28/NM, and O157:H7/NM.

Unrooted neighbor-joining tree was generated from allelic profiles of seven housekeeping genes (adk, fumC, gyrB, icd, mdh, purA, recA) [30] using the Phylip software package ( ST, sequence type; CC, clonal complex (at least six identical alleles); NM, non-motile; stx, Shiga toxin-encoding gene; stx−, stx-negative; stx+, stx-positive; SF, sorbitol-fermenting; NSF, non-sorbitol-fermenting. Strains of serotype O121:H19 differ by at least 4 alleles from all known sequence types and have therefore no assigned clonal complex. Scale bar, 5% estimated evolutionary distance.

Serological investigations

Serum samples were collected during the acute phase of HUS from 12 of 17 patients who shed stx−/eae+ E. coli O157 and from 10 of 26 patients who shed stx−/eae+ non-O157 strains. All 12 patients with E. coli O157 strains developed anti-O157 lipopolysaccharide (LPS) immunoglobulin M (IgM) antibodies. Among the 10 patients with non-O157 E. coli from whom serum samples were available, only the patient who shed E. coli ONT:H7 developed anti-O157 LPS IgM, suggesting a recent infection with E. coli O157 which probably precipitated the HUS. IgM antibodies to O157 LPS were not detected in the other nine sera from patients who shed stx−/eae+ E. coli O26:H11/NM (n = 5), O103:H2 (n = 1), O145:H28/NM (n = 2), and ONT:H6 (n = 1). Each of the five patients who excreted stx−/eae+ E. coli O26 had IgM antibodies to O26 LPS; presence of anti-O103 and anti-O145 LPS antibodies in the one and two patients, respectively, who shed stx−/eae+ E. coli strains of these serogroups could not be determined because of insufficient amount of the serum samples.

Characterization of HUS patients who excreted stx−/eae+ E. coli but not other pathogens

Twenty of 43 HUS patients who shed stx−/eae+ E. coli as the only pathogens were males and 23 were females. Thirty-seven patients for whom information about age was available were children between 5 months and 9 years (mean age, 31.3 months; median age, 24 months). The mean age of these patients was significantly lower than that of patients who shed EHEC strains (range, 4 months to 64 years, mean, 34.6 months; median, 27 months) (P = 0.003; Mann-Whitney U test). None of the 43 patients who excreted stx−/eae+ E. coli strains and nine (2.0%) of the 440 patients who excreted EHEC died during the acute phase of HUS.


Stxs produced by EHEC are considered the major precipitants of the microvascular endothelial injury that underlies HUS [1], [12]. These toxins and their encoding genes are also the major targets exploited in the laboratory diagnosis of EHEC infections [2], [31]. Our finding of stx-negative E. coli strains that are closely related to EHEC as the only putative bacterial pathogens in stools of ∼5% of patients with HUS during a long-term study sheds therefore new light into microbiological, diagnostic, epidemiological, and clinical aspects of this disorder.

Several lines of evidence support the hypothesis that these stx-negative strains represent derivatives of original infecting EHEC that lost the ability to express Stx (EHEC-LST), in these cases because of stx-bacteriophage excision during infection. First, the spectrum of serotypes of the stx-negative isolates is similar to that of EHEC strains isolated from HUS patients (Table 1); in both cases, serotype O157:H7/NM (including both non-sorbitol-fermenting [NSF] and sorbitol-fermenting [SF] strains) is the most frequent, being followed by serotypes O26:H11/NM, O145:H28/NM, and O103:H2/NM (Table 1). These serotypes are generally not excreted by healthy subjects [32; H. Karch, unpublished data]. The absence of serogroup O111, which was found in 2.5% of EHEC-excreting patients, among the HUS-associated EHEC-LST isolates (Table 1) is probably because stx1, which is the most prevalent stx in EHEC O111 [33] is encoded within a defective prophage, which has been immobilized in the EHEC genome [34], preventing the stx loss by phage excision. Also, the ratio between SF and NSF EHEC-LST O157 isolates (88% vs. 12%) (Table 1), while in contrast to that observed between SF and NSF EHEC O157 isolated from HUS (26% vs. 74%) (Table 1), is proportional to the greater frequency with which the stx loss occurs in SF EHEC O157:NM [21], [22]. Second, the EHEC-LST isolates share with EHEC of the corresponding serotypes non-stx virulence and fitness genes and belong to the same MLST clonal complexes. This demonstrates a common phylogeny and conservation of variable genome regions in the two groups of organisms. Third, the possibility of stx loss from EHEC O26:H11/NM and SF EHEC O157:NM during the course of HUS has been proposed in our previous study based on closely related molecular characteristics of stx-positive and stx-negative isolates from the initial and follow-up stools, respectively [21]; the stx loss has been confirmed in vitro [16]. Fourth, the genomic loci where stx-converting bacteriophages integrate into the genomes of EHEC O26:H11/NM [16] and O157:H7/NM [14], [15] were unoccupied in all stx−/eae+ isolates of these serotypes indicating that the stx loss resulted from the excision of stx-converting phages. Altogether, these data strongly suggest that the stx−/eae+ E. coli strains isolated from HUS patients were EHEC-LST.

Although the design of the study does not allow to determine whether the stx−/eae+ E. coli strains could be primary pathogens that triggered the HUS in patients from whom they were isolated, this seems to be unlikely, taking into account the paradigm that HUS is caused by Stx [1], [2]. However, because they have unoccupied stx-bacteriophage integration sites, the stx−/eae+ E. coli O26:H11/NM and O157:H7/NM strains can be transduced with stx-harboring phages and converted thus to EHEC, at least in vitro [16]. Whether such an event can occur during infection and whether it could trigger HUS remains to be established. Moreover, conditions favoring lysogenic conversion or stx loss in vivo are poorly understood [18].

The ratio between EHEC-LST (5.5%) and EHEC (55.9%) isolated in our study is ∼1∶10. The finding that every 10th patient with HUS, a condition that was most probably triggered by an EHEC infection, does not shed EHEC, but rather excretes EHEC-LST when stool is subjected to appropriate microbiological analysis, has important practical implications. First, the stx loss in an EHEC strain during infection can mislead epidemiological investigations because an stx-negative strain would not be, based on currently used criteria, considered to be epidemiologically related to stx-positive strains, even though of the same serotype. Therefore, the awareness of the possibility that a patient with HUS can excrete, in lieu of the original infecting EHEC, EHEC-LST which shares non-stx molecular characteristics with EHEC of the corresponding serotype, can assist epidemiologists to link correctly epidemiologically related cases, to identify the source of the infection and to trace modes of transmission. In such studies it is necessary to bear in mind that the loss of stx-harboring bacteriophages can alter pulsed-field gel electrophoresis patterns of the strains [15], [16], so that the epidemiologically related stx-positive and stx-negative strains can more or less differ in their fingerprints [16].

Second, microbiological identification of patients infected with EHEC O157:H7 early in illness is strongly associated with a good nephrologic outcome [1], probably because such an expeditious diagnosis prompts early volume expansion [35]. In patients excreting an EHEC-LST, the microbiological diagnosis may be delayed or the EHEC etiology of the disease is missed using tests that rely solely on the detection of stx genes or Stx production [31]. However, this concern might or might not be appropriate, depending on when in the course of the disease EHEC-LST replace the EHEC that almost certainly preceded the EHEC-LST. Whereas underdiagnosing EHEC-LST might not be clinically critical in patients with overt HUS who had already developed microvascular injury, the information about the presence of EHEC-LST in the stool (which may indicate continuing presence of the original EHEC in an amount undetectable by PCR stx screening) is of an important diagnostic value in patients with diarrhea, especially those with bloody diarrhea which often precedes HUS [1], [2], [5]. In such patients, a prompt diagnosis of EHEC-LST infection should alert the treating physician that the patient could develop HUS and should be monitored assiduously, receive isotonic volume expansion [35], and not be given antibiotics [36], [37] or antimotility agents [1], [38]. Clearly, we need better, and broader, microbiologic procedures to detect, in addition to stx or Stx, also non-stx/Stx EHEC targets.

How should EHEC-LST be detected? eae, which is present in the majority of EHEC isolated from HUS patients in Europe [2], [19] and the United States [7], [8], appears to be a quite appropriate additional diagnostic target. Specifically, based on our finding that eae-negative EHEC account for <4% of HUS-associated EHEC isolates in Germany [19] and assuming, based on the data from the present study, that stx loss occurs in ∼10% of the infecting EHEC, the using eae as a target to identify EHEC-LST would miss only ∼0.4% of such strains. This proportion of missed pathogens might be higher in regions where eae-negative EHEC account for a higher proportion of HUS isolates [10], [39]. In this case, the gene encoding the Stx-producing E. coli autoagglutinating adhesin (saa) [39], which is present in the majority of eae-negative EHEC associated with HUS [39], might be a suitable alternative to search for EHEC-LST. Optimal detection algorithms, and non-stx loci, depend on geographic and temporal-specific epidemiological trends, and for this reason it is necessary to continue microbiological surveillance. In this regard, it is critical to not abandon culture in favor of non-culture methodology, but to apply both modalities simultaneously to all stool specimens. In consideration of current epidemiology and etiology [1], [2], we believe that optimal diagnosis for both EHEC and EHEC-LST should consist of plating on sorbitol MacConkey (SMAC) agar (detection of NSF E. coli O157:H7/NM) and enterohemolysin agar (detection of the most frequent non-O157 serotypes based on the enterohemolytic phenotype) (Table 3) [9], [24], Stx or stx gene testing, and targeting eae (or saa) and sfpA (the latter for a specific detection of SF E. coli O157:NM) (Table 2) [23]. In culture-negative patients for whom serum samples are available, detection of antibodies against LPSs of the most frequent E. coli serogroups associated with HUS (both O157 and non-O157) can be an alternative approach to detect infection with both EHEC and EHEC-LST.

The application of stx/Stx-independent diagnostic strategies to identify EHEC-LST in HUS patients appears to be appropriate to consider for several reasons. First, stool samples from such patients are frequently collected only after HUS develops, i.e. ≥1 week after the onset of the prodromal diarrhea [1], as was true also for the majority of patients in our study. At this point in illness, EHEC might have been cleared [40] or stx might have been lost from infecting organisms [21]. In the latter case, using a non-stx diagnostic target such as eae or saa can still identify, with a high probability, the causative agent. Moreover, such diagnostic approaches would permit a prospective systematic clinical study to determine if stx loss by the infecting EHEC during the course of HUS might result in a less severe acute disease and/or a decreased rate of late sequelae.

Our study has two major limitations. First, although we systematically sought stx−/eae+ E. coli strains in stools that were negative for EHEC, as indicated by negative result of PCR screening for stx genes, we did not seek such strains in stool samples that contained EHEC. Stools that were stx-positive in PCR screening were only analyzed for stx-positive colonies. This approach rendered it impossible to determine if some of the patients had both stx−/eae+ E. coli strains and EHEC in the same stool, a situation that would indicate progressive loss of stx by the infecting EHEC population. Although poly-isolate analyses in other studies where a panel of markers were used including stx nucleic acid hybridization did not detect such a mixed population [41], [42], in these studies, stools were collected early in illness, and only five colonies were studied. Further studies targeting systematically both stx and eae (or other loci) in sequential stools from HUS patients are needed to determine the dynamic of stx loss during infection and to identify factors that could influence this process, such as serotype of the infecting EHEC, patient-related and/or environmental factors. Second, we do not have sufficient data to determine if antibiotics played a role in stx loss, as suggested in several experimental studies [14], [17].

In conclusion, at the time of microbiological analysis, an appreciable subset of patients with HUS shed no longer EHEC sensu stricto, but do excrete EHEC that lost stx. Diagnostic strategies need to be formulated to detect such pathogens and treating physicians should be immediately informed. Patients who shed such strains should be considered as potentially infected by EHEC and managed accordingly, at least until more data about the clinical significance of the EHEC-LST emerge. While not changing the paradigm that Stxs are the critical virulence determinant of EHEC responsible for HUS, our data do demonstrate the necessity of taking into account possible genetic changes of the pathogens during infection when developing appropriate diagnostic strategies and interpreting results of microbiological analyses.

Materials and Methods


During routine diagnostic work between 1996 and 2006, we sought stx−/eae+ E. coli and EHEC strains in stools (one stool per patient) from 787 epidemiologically unrelated patients with HUS. The patients were hospitalized in 23 pediatric nephrology centers in Germany and Austria described previously [5], with an extended period for patient enrollment until December 2006. Stools from patients who excreted stx−/eae+ E. coli strains and EHEC strains were collected between 5 and 14 days (median 9 days) and between 5 and 13 days (median 8 days), respectively, after the onset of prodromal diarrhea. The difference in the time of stool collection was not significant (P = 0.24, Mann-Whitney U test). HUS was defined as microangiopathic hemolytic anemia (hematocrit <30%, with evidence of the destruction of erythrocytes on a peripheral-blood smear), thrombocytopenia (platelet count <150,000/mm3), and renal insufficiency (serum creatinine concentration greater than the upper limit of the normal range for age) [36].

Identification of stx−/eae+ E. coli in stools

stx−/eae+ E. coli strains were sought in parallel with EHEC as described [21], [23]. Briefly, stool samples enriched in Hajna broth were specifically enriched for E. coli O157 using immunomagnetic separation with Dynabeads anti-E. coli O157 (Invitrogen, and magnetically separated organisms were cultured on SMAC agar and cefixime-tellurite (CT)-SMAC agar (Oxoid, To identify non-O157 E. coli strains, non-separated broth cultures were inoculated onto SMAC and enterohemolysin agar (Sifin, The overnight growth was harvested into saline and screened by PCR for stx1, stx2, eae, rfbO157 and sfpA genes [21], [23]; the latter two PCRs specifically detect E. coli O157 [23]. stx-positive stool cultures were further processed to isolate EHEC strains [21], [23]. From cultures which were stx-negative but eae-positive the eae-positive strains were isolated using colony blot hybridization with digoxigenin-labeled eae probe [21]. Among the 43 stx−/eae+ strains described here, 27 were isolated in this study and 16 (12 O157:H7/NM and four non-O157) in our previous studies [21], [22].

Phenotypic methods

Resulting isolates were biochemically confirmed as E. coli (API 20 E; bioMérieux, and serotyped [43]. Fermentations of sorbitol and rhamnose were detected on SMAC and rhamnose MacConkey agar (Sifin), respectively [24]. The enterohemolytic phenotype was sought on enterohemolysin agar and resistance to tellurite on CT-SMAC [25]. Stx activity in culture supernatants and stool filtrates was detected using the Vero cell assay [19]. Production of cytolethal distending toxin (CDT) was determined using Chinese hamster ovary cells [26].

Genotypic characterization

eae, presently known stx alleles [2], and other toxin (EHEC-hlyA, cdt-V) and adhesin (iha, lpfAO26, lpfAO157/OI 141, lpfAO157/OI 154, sfpA) genes were detected using established PCR protocols [19], [23], [24], [26], [27], [33], [44]. Moreover, the isolates were PCR tested for putative virulence genes located within O island 122 of EHEC O157:H7 strain EDL933 (efa1, sen, pagC) [11], [28], the ter gene cluster encoding tellurite resistance [25], and irp2 and fyuA, which are components of the iron uptake system encoded on the high pathogenicity island [29]. eae genes were subtyped [45] and genotypes of the flagellin-encoding fliC gene were determined [9], [33]. The intact or occupied status of chromosomal loci that serve as phage integration sites (yehV, wrbA, yecE) was investigated using PCR primers and conditions described previously [14][16].


MLST was performed by analyzing internal fragments of seven housekeeping genes (adk, fumC, gyrB, icd, mdh, purA, recA) [16], [30]. The alleles and sequence types were assigned in accordance with the E. coli MLST website ( The genetic relationships between different sequence types were determined using eBURST [46] and a phylogenetic tree based on neighbor-joining analysis was constructed using the Phylip package (

Detection of additional classic bacterial enteric pathogens

Salmonella, Shigella, and Yersinia spp., and Campylobacter jejuni were sought using standard procedures [47][49].

Serological investigation

IgM antibodies against the O157 and O26 LPS antigens were sought in sera from acute phase of HUS using an immunoblot [21].

Statistical analysis

The non-parametric Mann-Whitney U (Wilcoxon) two-sample test for independent sample groups and OpenStat2 Software ( were used for statistical analysis. P values <0.05 were considered significant.


We thank Phillip I. Tarr (Washington University School of Medicine, St. Louis, Mo.) for extensive and fruitful discussions on the manuscript, and Nadine Brandt and Margret Junge for excellent technical assistance.

Author Contributions

Conceived and designed the experiments: MB LZ HK. Performed the experiments: AF MB RK Cv AM. Analyzed the data: AF MB RK Cv LZ HK AM. Contributed reagents/materials/analysis tools: AF RK Cv LZ HK. Wrote the paper: MB HK AM. Other: Designed Figure 1 for the manuscript: AM RK. Communicated with treating physicians about clinical data: AF. Supervised the project: HK. Secured funds to support the study: HK.


  1. 1. Tarr PI, Gordon CA, Chandler WL (2005) Shiga toxin-producing Escherichia coli and the haemolytic uraemic syndrome. Lancet 365: 1073–1086.
  2. 2. Karch H, Tarr PI, Bielaszewska M (2005) Enterohaemorrhagic Escherichia coli in human medicine. Int J Med Microbiol 295: 405–418.
  3. 3. Siegler RL (2003) Postdiarrheal Shiga toxin-mediated hemolytic uremic syndrome. JAMA 290: 1379–1381.
  4. 4. Lynn RM, O'Brien SJ, Taylor CM, Adak GK, Chart H, et al. (2005) Childhood hemolytic uremic syndrome, United Kingdom and Ireland. Emerg Infect Dis 11: 590–596.
  5. 5. Gerber A, Karch H, Allerberger F, Verweyen HM, Zimmerhackl LB (2002) Clinical course and the role of Shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997–2000, in Germany and Austria: a prospective study. J Infect Dis 186: 493–500.
  6. 6. Tozzi AE, Caprioli A, Minelli F, Gianviti A, De Petris L, et al. (2000) Shiga toxin-producing Escherichia coli infections associated with hemolytic uremic syndrome, Italy, 1988–2000. Emerg Infect Dis 9: 106–108.
  7. 7. Banatvala N, Griffin PM, Greene KD, Barrett TJ, Bibb WF, et al. (2001) The United States national prospective hemolytic uremic syndrome study: microbiologic, serologic, clinical, and epidemiologic findings. J Infect Dis 183: 1063–1070.
  8. 8. Brooks JT, Sowers EG, Wells JG, Greene KD, Griffin PM, et al. (2005) Non-O157 Shiga toxin-producing Escherichia coli infections in the United States, 1983–2002. J Infect Dis 192: 1422–1429.
  9. 9. Sonntag A, Prager R, Bielaszewska M, Zhang W, Fruth A, et al. (2004) Phenotypic and genotypic analyses of enterohemorrhagic Escherichia coli O145 strains from patients in Germany. J Clin Microbiol 42: 954–962.
  10. 10. Elliott EJ, Robins-Browne RM, O'Loughlin EV, Bennett-Wood V, Bourke J, et al. (2001) Nationwide study of haemolytic uraemic syndrome: clinical, microbiological, and epidemiological features. Arch Dis Child 85: 125–131.
  11. 11. Karmali MA, Mascarenhas M, Shen S, Ziebell K, Johnson S, et al. (2003) Association of genomic O island 122 of Escherichia coli EDL 933 with verocytotoxin-producing Escherichia coli seropathotypes that are linked to epidemic and/or serious disease. J Clin Microbiol 41: 4930–4940.
  12. 12. Sandvig K (2001) Shiga toxins. Toxicon 39: 1629–1635.
  13. 13. Richardson SE, Karmali MA, Becker LE, Smith CR (1988) The histopathology of the hemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli infections. Hum Pathol 19: 1102–1108.
  14. 14. Shaikh N, Tarr PI (2003) Escherichia coli O157:H7 Shiga toxin-encoding bacteriophages: integrations, excisions, truncations, and evolutionary implications. J Bacteriol 185: 3596–3605.
  15. 15. Bielaszewska M, Prager R, Zhang W, Friedrich AW, Mellmann A, et al. (2006) Chromosomal dynamism in progeny of outbreak-related sorbitol-fermenting enterohemorrhagic Escherichia coli O157:NM. Appl Environ Microbiol 72: 1900–1909.
  16. 16. Bielaszewska M, Prager R, Köck R, Mellmann A, Zhang W, et al. (2007) Shiga toxin gene loss and transfer in vitro and in vivo during enterohemorrhagic Escherichia coli O26 infection in humans. Appl Environ Microbiol 73: 3144–3150.
  17. 17. Zhang X, McDaniel AD, Wolf LE, Keusch GT, Waldor MK, et al. (2000) Quinolone antibiotic induces Shiga toxin-encoding bacteriophages, toxin production and death in mice. J Infect Dis 181: 664–670.
  18. 18. Wagner PL, Waldor MK (2002) Bacteriophage control of bacterial virulence. Infect Immun 70: 3985–3993.
  19. 19. Bielaszewska M, Friedrich AW, Aldick T, Schurk-Bulgrin R, Karch H (2006) Shiga toxin activatable by intestinal mucus in Escherichia coli isolated from humans: predictor for a severe clinical outcome. Clin Infect Dis 43: 1160–1167.
  20. 20. Donnenberg MS, Tzipori S, McKee ML, O'Brien AD, Alroy J, et al. (1993) The role of the eae gene of enterohemorrhagic Escherichia coli in intimate attachment in vitro and in a porcine model. J Clin Invest 92: 1418–1424.
  21. 21. Mellmann A, Bielaszewska M, Zimmerhackl LB, Prager R, Harmsen D, et al. (2005) Enterohemorrhagic Escherichia coli in human infection: in vivo evolution of a bacterial pathogen. Clin Infect Dis 41: 785–792.
  22. 22. Friedrich AW, Zhang W, Bielaszewska M, Mellmann A, Köck R, et al. (2007) Prevalence, virulence profiles, and clinical significance of Shiga toxin-negative variants of enterohemorrhagic Escherichia coli O157 infection in humans. Clin Infect Dis 45: 39–45.
  23. 23. Friedrich AW, Nierhoff KV, Bielaszewska M, Mellmann A, Karch H (2004) Phylogeny, clinical associations, and diagnostic utility of the pilin subunit gene (sfpA) of sorbitol-fermenting, enterohemorrhagic Escherichia coli O157:H. J Clin Microbiol 42: 4697–4701.
  24. 24. Bielaszewska M, Zhang W, Tarr PI, Sonntag AK, Karch H (2005) Molecular profiling and phenotype analysis of Escherichia coli O26:H11 and O26:NM: secular and geographic consistency of enterohemorrhagic and enteropathogenic isolates. J Clin Microbiol 43: 4225–4228.
  25. 25. Bielaszewska M, Tarr PI, Karch H, Zhang W, Mathys W (2005) Phenotypic and molecular analysis of tellurite resistance among enterohemorrhagic Escherichia coli O157:H7 and sorbitol-fermenting O157:NM clinical isolates. J Clin Microbiol 43: 452–454.
  26. 26. Janka A, Bielaszewska M, Dobrindt U, Greune L, Schmidt MA, et al. (2003) Cytolethal distending toxin gene cluster in enterohemorrhagic Escherichia coli O157:H- and O157:H7: characterization and evolutionary considerations. Infect Immun 71: 3634–3638.
  27. 27. Toma C, Martinez Espinosa E, Song T, Miliwebsky E, Chinen I, et al. (2004) Distribution of putative adhesins in different seropathotypes of Shiga toxin-producing Escherichia coli. J Clin Microbiol 42: 4937–4946.
  28. 28. Janka A, Bielaszewska M, Dobrindt U, Karch H (2002) Identification and distribution of the enterohemorrhagic Escherichia coli factor for adherence (efa1) gene in sorbitol-fermenting Escherichia coli O157:H. Int J Med Microbiol 292: 207–214.
  29. 29. Karch H, Schubert S, Zhang D, Zhang W, Schmidt H, et al. (1999) A genomic island, termed “high pathogenicity island”, is present in certain non-O157 Shiga toxin-producing Escherichia coli clonal lineages. Infect Immun 67: 5994–6001.
  30. 30. Wirth T, Falush D, Lan R, Colles F, Mensa P, et al. (2006) Sex and virulence in Escherichia coli: an evolutionary perspective. Mol Microbiol 60: 1136–1151.
  31. 31. Park CH, Kim HJ, Hixon DL (2002) Importance of testing stool specimens for Shiga toxins. J Clin Microbiol 40: 3542–3543.
  32. 32. Beutin L, Marches O, Bettelheim KA, Gleier K, Zimmermann S, et al. (2003) HEp-2 cell adherence, actin aggregation, and intimin types of attaching and effacing Escherichia coli strains isolated from healthy infants in Germany and Australia. Infect Immun 71: 3995–4002.
  33. 33. Zhang W, Mellmann A, Sonntag AK, Wieler L, Bielaszewska M, et al. (2007) Structural and functional differences between disease-associated genes of enterohaemorrhagic Escherichia coli O111. Int J Med Microbiol 297: 17–26.
  34. 34. Creuzburg K, Kohler B, Hempel H, Schreier P, Jacobs E, et al. (2005) Genetic structure and chromosomal integration site of the cryptic prophage CP-1639 encoding Shiga toxin. Microbiology 151: 941–950.
  35. 35. Ake JA, Jelacic S, Ciol MA, Watkins SL, Murray KF, et al. (2005) Relative nephroprotection during Escherichia coli O157:H7 infections: Association with intravenous volume expansion. Pediatrics 115: 673–680.
  36. 36. Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI (2000) The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. New Engl J Med 342: 1930–1936.
  37. 37. Zimmerhackl LB (2000) E. coli, antibiotics, and the hemolytic-uremic syndrome. N Engl J Med 342: 1990–1991.
  38. 38. Cimolai N, Basalyga S, Mah DG, Morrison BJ, Carter JE (1994) A continuing assessment of risk factors for the development of Escherichia coli O157:H7-associated hemolytic uremic syndrome. Clin Nephrol 42: 85–89.
  39. 39. Paton AW, Srimanote P, Woodrow MC, Paton JC (2001) Characterization of Saa, a novel autoagglutinating adhesin produced by locus of enterocyte effacement-negative Shiga toxigenic Escherichia coli strains that are virulent for humans. Infect Immun 69: 6999–7009.
  40. 40. Tarr PI, Neill MA, Clausen CR, Watkins SL, Christie DL, et al. (1990) Escherichia coli O157:H7 and the hemolytic uremic syndrome: importance of early cultures in establishing the etiology. J Infect Dis 162: 553–556.
  41. 41. Bokete TN, Whittam TS, Wilson RA, Clausen CR, O'Callahan CM, et al. (1997) Genetic and phenotypic analysis of Escherichia coli with enteropathogenic characteristics isolated from Seattle children. J Infect Dis 175: 1382–1389.
  42. 42. Klein EJ, Stapp JR, Clausen CR, Boster DR, Wells JG, et al. (2002) Shiga toxin-producing Escherichia coli in children with diarrhea: a prospective point-of-care study. J Pediatr 141: 172–177.
  43. 43. Prager R, Strutz U, Fruth A, Tschäpe H (2003) Subtyping of pathogenic Escherichia coli strains using flagellar (H)-antigens: serotyping versus fliC polymorphisms. Int J Med Microbiol 292: 477–486.
  44. 44. Jelacic JK, Damrow T, Chen GS, Jelacic S, Bielaszewska M, et al. (2003) Shiga toxin-producing Escherichia coli in Montana: bacterial genotypes and clinical profiles. J Infect Dis 188: 719–729.
  45. 45. Zhang WL, Kohler B, Oswald E, Beutin L, Karch H, et al. (2002) Genetic diversity of intimin genes of attaching and effacing Escherichia coli strains. J Clin Microbiol 40: 4486–4492.
  46. 46. Feil EJ, Li BC, Aanensen DM, Hanage WP, Spratt BG (2004) eBURST: inferring patterns of evolutionary descent among clusters of related bacterial genotypes from multilocus sequence typing data. J Bacteriol 186: 1518–1530.
  47. 47. Bopp CA, Brenner FW, Fields PJ, et al. (2003) Escherichia, Shigella, and Salmonella. In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH, editors. Manual of clinical microbiology. 8th ed. Washington DC: American Society for Microbiology. pp. 654–671.
  48. 48. Bockemühl J, Wong JD (2003) Yersinia. In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH, editors. Manual of clinical microbiology. 8th ed. Washington DC: American Society for Microbiology. pp. 672–683.
  49. 49. Nachamkin I (2003) Campylobacter and Arcobacter. In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH, editors. Manual of clinical microbiology. 8th ed. Washington DC: American Society for Microbiology. pp. 902–914.